
November 6, 2026 · 7 min read
OPM Backsolve vs PWERM: Key Differences Explained
Two ways to value the common stock of a private company. How each one works, when each fits and what it means for your stock options.
- Valuation
OPM vs PWERM comes down to where the value starts. An OPM backsolve starts from the price investors just paid in a funding round and works back to the value of every share class. PWERM starts from possible exits, such as an IPO or a sale, and weighs each by its chance. The backsolve suits a company far from an exit. PWERM suits one with a clear exit in view.
If you hold stock options in a private company, these methods set the value of your common stock. That value becomes the exercise price on new grants, so it affects what you pay later. If you invest in a startup, it explains why common stock is valued far below the price you paid for preferred.
$1.00 → $0.25
Inozyme’s preferred share price in November 2018 and its common stock value from an OPM backsolve that month
$0.27 → $0.37
Inozyme’s common stock value before and after it switched to a hybrid with an IPO scenario
12 months
Maximum age of an independent appraisal that US tax rules presume reasonable
20%
Extra federal tax, plus interest, on pay caught by a Section 409A failure
What Is the Main Difference Between OPM Backsolve and PWERM?
The table compares the two methods on what each is, who uses it, its inputs, legal and tax treatment, the main risk, how it relates to liquidity and a typical example. Both methods answer the same question. They answer it from different starting points.
The backsolve anchors on what investors paid. PWERM anchors on what an exit might pay. A hybrid uses both
As of November 2026 · Treas. Reg. §1.409A-1(b)(5)(iv)(B); Inozyme Pharma Form S-1 (07.02.2020). US rules; methods vary by appraiser.
How the Backsolve and PWERM Reach a Number
OPM Backsolve
The OPM backsolve begins with a fact. Investors just bought preferred stock at a known price. The appraiser builds an option model of the whole cap table. Each class is treated as a call option on the company’s value, a right that pays only above a certain level. The appraiser then searches for the total equity value at which the model gives that exact preferred price.
Once the total is found, the model splits it among the classes. Common stock sits behind the liquidation preference, so it gets less per share. A discount for lack of marketability then lowers it further, because common shares cannot be sold easily.
PWERM
PWERM begins with a forecast. The appraiser lists the ways the company could end: an IPO, a sale or a wind-down. For each one, it estimates the exit value and the payout to each class. It weights the payouts by probability and discounts them to today.
An illustrative case, with invented numbers. A company expects one of three outcomes in two years:
- IPO, 50% chanceCommon stock worth $12 a share
- Sale, 35% chanceCommon stock worth $6 a share
- Wind-down, 15% chanceCommon stock worth $0
- ResultWeighted value $8.10 → $5.18 after a 25% yearly discount rate → $4.15 after a 20% marketability discount
A hybrid method is a PWERM in which one scenario is valued with an OPM. Inozyme used one in March 2020. It valued an IPO scenario from recently listed peers and an unspecified exit with a backsolve.
Which Is Better for Investors or Employees?
Neither method favors one side by design. The test is whether the method fits the company’s facts. A backsolve fits when a fresh round exists and no exit is planned. PWERM fits when bankers are hired and an IPO window can be modeled.
For employees, the method matters through the exercise price. A lower common value means a lower price on new options. A value that is too low invites tax trouble, so appraisers must defend every input. For investors, the method explains the gap between their preferred price and the common value.
Inozyme shows the gap. It sold Series A preferred at $1.00 a share on November 8, 2018. Its appraisal as of November 30, 2018 valued the common stock at $0.25. As an IPO came into view, it moved to a hybrid. The common value rose from $0.27 in May 2019 to $0.37 in March 2020.
How the Tax Treatment Compares
The tax rules are the same for both methods. Under Section 409A, private company stock must be valued by the reasonable application of a reasonable method. The regulations list factors such as the company’s assets, its future cash flows and recent arm’s-length sales of its stock. They do not name the OPM or PWERM.
An independent appraisal dated no more than 12 months before a grant is presumed reasonable. The IRS can overturn it only by showing the method, or how it was applied, was grossly unreasonable. This appraisal is the 409A valuation. To keep that presumption, a company refreshes its appraisal at least every 12 months.
If options are priced below fair market value, they can fall under Section 409A. The holder then owes income tax early, interest and an extra 20% tax. The method choice does not change these rules. It changes the number the rules are applied to.
OPM Backsolve vs PWERM Pros and Cons: A Verdict on Each
OPM Backsolve
- For
- It starts from a real price paid by outside investors. It needs no forecast of exit values or their odds. It handles complex share classes in one model.
- Against
- The round may include terms the common stock lacks. Volatility and time-to-exit guesses can move the result a lot. It ignores a known exit plan.
Verdict: the backsolve is the natural choice soon after a priced round, when no exit is in sight. Its strength is the anchor in a real transaction. Its weakness is that the anchor ages, and a stale round gives a stale value.
PWERM
- For
- It shows how each share class fares in each exit. It reflects a planned IPO or sale directly. Its logic is easy to follow.
- Against
- Every probability and exit value is a judgment. Far from an exit, the scenarios are hard to support. Small changes in the odds can swing the result.
Verdict: PWERM fits a company preparing an IPO or a sale. The closer the exit, the easier the scenarios are to defend. Many appraisers use a hybrid at that stage, as Inozyme did, to keep a backsolve for the case where the IPO does not happen.
Use the backsolve when a recent round is the main evidence of value. Use PWERM or a hybrid when a specific exit is close enough to model.
What the Method Means for Your Shares
If you receive options, ask which method the latest appraisal used and its date. A value more than 12 months old loses its presumption. A new round or a planned IPO can also make it stale. For how the common value relates to the round price, see 409A valuation vs preferred price.
If you buy shares in a secondary sale, remember that a 409A value is a tax figure. Your price is set by the deal. For the wider toolkit, see private company valuation and common stock vs preferred stock.
Common Mistakes
- Reading the 409A value as a market priceIt values common stock for tax and accounting. Buyers in a secondary sale may pay more or less.
- Expecting common to equal the preferred pricePreferred stock is paid first in an exit. Inozyme’s common was valued at a quarter of its preferred price.
- Treating one method as the IRS’s choiceThe rules require a reasonable method. They do not name either one.
- Ignoring the dateA value is reasonable for 12 months at most. A new round or IPO plan can age it sooner.
The Terms This Page Uses
- OPM backsolve
- A method that finds the total company value implied by a recent round price, then splits it among share classes with an option model.
- PWERM
- The probability-weighted expected return method. It values share classes across possible exits, weighted by probability and discounted to today.
- Hybrid method
- A PWERM in which one scenario is valued with an option pricing method.
- Option pricing method (OPM)
- A model that treats each share class as a call option on the whole company’s value.
- Call option
- A right that has value only when the underlying value rises above a set level.
- Liquidation preference
- The right of preferred holders to be paid back before common holders in a sale or wind-down.
- Discount for lack of marketability
- A reduction for shares that cannot be sold easily, applied after the method sets a value.
- 409A valuation
- An appraisal of private company common stock used to price stock options under US tax rules.
- Arm’s-length transaction
- A sale between unrelated parties, each acting in its own interest.
What People Ask About OPM and PWERM
No. The Section 409A regulations require a reasonable method applied reasonably. They list factors to consider, including recent arm’s-length sales of the stock, but they name neither method.
Yes. Inozyme valued its common stock with a backsolve through May 2019. By March 2020, ahead of its IPO filing, it used a hybrid with an IPO scenario.
Preferred holders are paid first in an exit, and common shares are hard to sell. Both methods capture the first point. A marketability discount captures the second.
It is a PWERM in which one scenario uses an option model. A common setup values an IPO scenario directly and an uncertain exit with a backsolve.
It depends on events. An appraisal is presumed reasonable for up to 12 months. A new round, a planned IPO or a big change in the business can make it stale sooner.
Where Every Rule on This Page Comes From
Figures were last checked on November 6, 2026. The rules are United States federal tax rules. Each appraisal follows its own assumptions, and a company’s figures are the ones in its own filings.
- 01Code of Federal Regulations (Cornell LII)Current ruleTreas. Reg. §1.409A-1(b)(5)(iv)(B): reasonable valuation method, factors incl. recent arm’s-length transactions, 12-month limit and appraisal presumption
- 02United States Code (Cornell LII)Current law26 U.S.C. §409A(a)(1): income inclusion, interest and additional 20% tax
- 03Inozyme Pharma, Inc. (SEC EDGAR)07.02.2020Form S-1: backsolve and OPM through 05.31.2019, hybrid method as of 03.31.2020, common values $0.13 to $0.37, Series A at $1.00
- 04AICPA & CIMA01.16.2026Working draft of the updated guide on valuing private company equity issued as compensation
This page explains how a market works. It is not investment advice, not a recommendation of any security, strategy or company, and not an offer to sell or a solicitation to buy anything. Private companies may never list or be acquired, positions in them can be illiquid for years, and the entire amount invested can be lost. Figures are accurate as of the dates shown and change. Requirements for investor status, and the tax treatment of a private holding, differ by jurisdiction — the jurisdiction is named wherever this page discusses either. Prepared by the AXEVIL Capital research team.
What closed on the private market in the past two weeks
The rounds that priced, the tender offers that opened and the listings that filed — with the structure of each deal and the date on every figure. Written by the team that reads the paperwork.


